% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • comsensea comsensea Nov 7, 2013 4:30 PM Flag

    Compelling Data--New Target $10

    In the 18-patient study evaluating Geron’s medicine imetelstat, 44 percent experienced clinical improvement, partial remission or complete remission, according to data posted today. That included four participants who had reversal of bone marrow fibrosis, or scarring. The study was run by the Mayo Clinic with funding from Geron.

    “The efficacy data appears compelling and is certainly sufficient for progression into a Geron-sponsored Phase 2 study,” Charles Duncan an analyst with Piper Jaffray & Co., wrote today in a research note. He raised his price target for the shares to $10 from $6.

    After a median follow-up of 3.2 months, 89 percent of patients remained on Geron’s therapy, according to the data. The study will be reported next month at the American Society of Hematology meeting in New Orleans.

2.68Jun 30 4:00 PMEDT